Can a PARP Inhibitor-Chemotherapy Combination Improve Advanced Breast Cancer Outcomes?

The addition of the PARP inhibitor veliparib to carboplatin  and paclitaxel offered significant improvement to patients with HER2-negative breast cancer.

Source: CancerNetwork - October 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news